Cancer survivor completes epic 2,000-mile canoe journey with loyal dog

Four years after a single, experimental immune-cell infusion cleared his cancer, 67-year-old Frank Carter completed a solo, more than 2,000-mile canoe trip down the Missouri River with his dog, underscoring both a personal recovery and the growing promise of modern immunotherapy. The journey — and Carter’s remission — were detailed by the Moffitt Cancer Center and local reports from FOX 13.

Carter spent 64 days on the water in a cedar-strip canoe he built himself, starting in Montana and finishing near St. Louis. He and his canine companion camped along the banks and pushed through severe weather, including high winds, storms and hail, according to the accounts.

From endurance adventurer to cancer patient

Before his diagnosis, Carter was already an experienced long-distance traveler: a five-month trek on the Appalachian Trail in 2019 and an eight-week bicycle ride across the country in 2020. But after a routine 5K in 2021 left him unusually exhausted, blood tests revealed a serious problem.

Physicians found that Carter had been diagnosed with mantle cell lymphoma, a rare blood cancer that affects certain white blood cells. He initially received 15 rounds of chemotherapy in Orlando, which reduced the disease but did not eliminate it entirely.

Turning to engineered immune cells

When scans showed lingering cancer, Carter sought treatment at the Moffitt Cancer Center in Tampa and received CAR T-cell therapy. The procedure removes a patient’s T-cells, engineers them in the lab to recognize cancer cells, and returns them to the bloodstream so they can target and destroy the tumor.

Dr. Michael Jain, an oncologist at Moffitt, explained to local media that the modified cells carry a receptor that allows them to detect cancer cells the tumor had been hiding from — effectively retraining the immune system to fight back.

• Diagnosis: Mantle cell lymphoma, detected after persistent fatigue following a 5K race (2021).
• Initial treatment: 15 rounds of chemotherapy in Orlando; partial response.
• Advanced therapy: Single infusion of CAR T-cell therapy at Moffitt Cancer Center.
• Outcome: Cancer-free for four years following the infusion.
• Recent milestone: Completed a 2,000+ mile Missouri River trip over 64 days with his dog, Amos.

Carter says the presence of his dog, Amos, was a constant source of comfort; he adopted the dog shortly before starting treatment. “I told myself I was going to beat this,” Carter said in an interview with Moffitt’s patient publication, describing the emotional support Amos provided through therapy and recovery.

Researchers and clinicians view cases like Carter’s as meaningful examples of how cellular immunotherapies can produce durable remissions for certain blood cancers. While results vary by disease type and patient, the growing body of follow-up data is important for patients and physicians weighing treatment options.

For Carter, the river trip was both a personal triumph and a statement about life after cancer: a demanding physical challenge completed with the resilience of someone who has endured intensive treatment and come out on the other side.